101 spots : Find the primary site

Abstract is not required for Clinical Imagesis not required for Clinical Images (This page in not part of the published article.) International Journal of Case Reports and Images, Vol. 6 No. 11, November 2015. ISSN – [0976-3198] Int J Case Rep Images 2015;6(11):727–729. www.ijcasereportsandimages.com Bera et al. 727 CASE REPORT OPEN ACCESS 101 spots: Find the primary site Geraldine Bera, Gabriel Malouf, Nathanaëlle Yeni, Charlotte Lepoutre-Lussey


CliNiCAl imAgES PEER REviEwEd | OPEN ACCESS
tomography/computed tomography ( 18 [F]-FDG PET/CT) scan highlighted intense whole-body disseminated uptake ( Figure 1A), in particular from the oral cavity to pyriform sinus ( Figure 1B), in the subcutaneous tissues ( Figure 1C), on bone, pancreas ( Figure 1D) and a moderate uptake on the right upper lung lobe probably corresponding to a pleomorphic PSC recurrence ( Figure 1E, 1F). Thus these findings have suggested a distant metastatic relapse of the PSC associated with a loco-regional recurrence of OSCC. Surprisingly, histological analysis of subcutaneous biopsies ( Figure 1G) concluded a well-differentiated SCC and immunostaining for thyroid transcription factor-1 (TTF-1) was negative.

DIsCUssIoN
Pulmonary sarcomatoid carcinoma is a rare, poorly differentiated subtype of non-small cell lung cancer accounting for 0.1-0.4% of all lung malignancies. They occur mostly in smoking males, at an average age of 60 years. With a high frequency of local recurrence and distant metastatio, they are responsible of an aggressive clinical course. Microscopically, this poor prognostic disease is the result of a biphasic proliferative malignant cells with both carcinoma and sarcomatoid components. Immunohistochemically, TTF-1, a specific marker of thyroid and pulmonary tumors such as adenocarcinoma and small cell carcinoma, is find to be positive in more than 50% of PSCs [1]. Head and neck squamous cell carcinoma (HNSCC), as far as they are concerned, preferentially metastasise to cervical lymph nodes. They have an uncommon hematogenous spread varying from 4.2-23.8%, up to 57% at autopsies on the lungs (80%), mediastinal nodes (34%), bone (31%) and liver (31%). Distant metastatic clearly affect the prognosis of HNSCCs and if not present at initial presentation it usually becomes apparent within two years [2]. Even so their clinicopathological predictive factors of occurrence are the site of the primary tumor (oropharynx, hypopharynx and larynx), multilevel nodal involvement in neck and primary tumor invasion into muscular, bone or cartilage ; metastatic screening by 18 [F]-FDG PET/CT can detect them early, before the onset of medical complications [3]. Detection of occult disseminated disease without curative options allow avoiding all futile treatment, counseling patients about prognosis and optimizing their quality of life [4]. Cancer-related hypercalcemia is most common in patients with lung, breast, head and neck and kidney cancer. It could be related either to osteolysis of the severe bone metastases -that was probably the reason for this atypical patient-or a paraneoplastic syndrome. Having a strong correlation with the stage of the primary tumor and the development of recurrence or metastasis, hypercalcemia has an adverse impact on survival of OSCC. Its early recognition could help to recognize occult neoplasms leading to a proper therapeutic strategy and so prolong survival with a better quality of life [5].

CoNCLUsIoN
This atypical case illustrates the utility of wholebody 18 Fluorine-fluorodeoxyglucose positron emission tomography computed tomography ( 18 [F]-FDG PET/CT) scan in the follow-up of head and neck squamous cell carcinoma (HNSCC) that can have a fatal issue due to distant metastatic and their resulting metabolic disorders such as hypercalcemia, more than their common local aggressive growth. Screening progression in these patients may help to anticipate the complications that are difficult to be managed.

Edorium Journals: An introduction
Edorium Journals Team

But why should you publish with Edorium Journals?
In less than 10 words -we give you what no one does.

Vision of being the best
We have the vision of making our journals the best and the most authoritative journals in their respective specialties. We are working towards this goal every day of every week of every month of every year.

Exceptional services
We care for you, your work and your time. Our efficient, personalized and courteous services are a testimony to this.

Editorial Review
All manuscripts submitted to Edorium Journals undergo pre-processing review, first editorial review, peer review, second editorial review and finally third editorial review.

Peer Review
All manuscripts submitted to Edorium Journals undergo anonymous, double-blind, external peer review.

Early View version
Early View version of your manuscript will be published in the journal within 72 hours of final acceptance.

Manuscript status
From submission to publication of your article you will get regular updates (minimum six times) about status of your manuscripts directly in your email.

Most Favored Author program
Join this program and publish any number of articles free of charge for one to five years.

Favored Author program
One email is all it takes to become our favored author. You will not only get fee waivers but also get information and insights about scholarly publishing.

Institutional Membership program
Join our Institutional Memberships program and help scholars from your institute make their research accessible to all and save thousands of dollars in fees make their research accessible to all.

Our presence
We have some of the best designed publication formats. Our websites are very user friendly and enable you to do your work very easily with no hassle.

Something more...
We request you to have a look at our website to know more about us and our services.
We welcome you to interact with us, share with us, join us and of course publish with us.

Invitation for article submission
We sincerely invite you to submit your valuable research for publication to Edorium Journals.

Six weeks
You will get first decision on your manuscript within six weeks (42 days) of submission. If we fail to honor this by even one day, we will publish your manuscript free of charge.

Four weeks
After we receive page proofs, your manuscript will be published in the journal within four weeks (31 days). If we fail to honor this by even one day, we will publish your manuscript free of charge and refund you the full article publication charges you paid for your manuscript.